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“Invasive giant prolactinoma” is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels
of >1000 ng/dL and mass related clinical symptoms. Here we report a patient with a giant prolactinoma presented
with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment
and high prolactin level.
The patient was treated with cabergoline, levothyroxin and prednisolone. After 18 months, tumor size markedly
reduced, associated with adrenal function and visual field improvement, but central hypogonadism and secondary
hypothyroidism persisted.
Previous studies showed normalization of thyrotropin secretion after treatment but it remained low in our patient
even after 18 months follow up.
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Prolactinoma is the most common pituitary adenoma [1]
which causes infertitity, menstrual irregularity and galac-
torrhea [2,3] in women and hypogonadism, decreased
libido, infertility, erectile dysfunction and gynecomastia
[4,5] in men.
In the present report we describe an unusuall giant
prolactin – producing macroadenoma of pituitary and
its response to cabergoline (a dopamine agonist).Case presentation
A 29 year – old married man was referred to us with
headache, blurred vision, diplopia, decreased libido and
weight gain from 12 months ago. He was married but did
not have child. Laboratory evaluations showed prolactin
levels as high as 12000 ng/mL (1.8–20) and further eva-
luations revealed central hypogonadism, secondary hypo-
thyroidism, adrenal insufficiency and normal IGF1 level
(Table 1). Pituitary MRI showed a large pituitary solid –
cystic mass with suprasellar and left cranial fossa exten-
sion measuring 5.5 × 5.0 × 2.5 cm in dimension (Figure 1)
and perimetry detected right side temporal hemianopia.
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distribution, and reproduction in any mediumtwice a week, levothyroxin 0.1 mg daily and prednisolone
7.5 mg resulted in visual improvement in one month.
Prolactin level decreased to 222 ng/ml after 3 months but
impotence and decreased libido didn’t show any improve-
ment. Testosterone level was 1.32 ng/mL (2.8–8). He was
started on testosterone (250 mg IM each 3 weeks) and
cabergoline dose increased to 3 mg per week. One year
after treatment, prolactin level reached to 165 ng/mL;
ACTH stimulation test (Synacthen 0.25 mg IV injection
and plasma cortisol measurement before, 30 and 60 min
after administration) results were normal. So we discon-
tinue prednisolone. Eighteen months later perimetry
test showed normal results, prolactin level diminished
to 71.5 ng/mL and tumor size markedly reduced on
MRI to 2.2 × 2.3 × 1.2 cm in dimention (Figure 2) but
central hypogonadism and secondary hypothyroidism per-
sisted (Table 1).Conclusion
Pituitary tumors larger than 4 cm in size are termed
“giant adenomas” [6]. “Invasive giant prolactinoma” is
defined as : 1) tumor diameter of >4 cm; 2) serum pro-
lactin >1000 ng/mL; and 3) clinical symptoms induced
by hyperprolactinemia or mass effect [7]. Most women
lactotroph adenomas are microadenoma, however the
men adenomas are usually larger [8]. Giant prolactinomatral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Hormonal evaluation before and after treatment
Normal range Before treatment After treatment
Prolactin 1.8 – 20 ng/mL 12000 71.5
IGF- I 219 – 614.4 ng/mL 120 230
FSH 1.4 – 15.4 mIU/mL 0.6 3.1
LH 1.2 – 7.8 mIU/mL 0.8 2.7
Testosterone 2.8 – 8 ng/mL <0.02 1
Cortisole 6.2 – 14.4 micg/dL 0.4 10
Cortisole 30 minafter ACTH injection 4.4 μg/dL 22.2 μg/Dl
Cortisole 60 min after ACTH injection 5.2 μg/dL 34.1 μg/Dl
ACTH 7.2 – 63 pg/dL 8.8
T4 5.1 – 14 micg/dL 5.5 8.2
TSH 0.5 – 5 mU/L 2.05 0.2
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gical removal of giant tumor is difficult and biochemical
cure is rare [11,12].
In prolactin – secreting macroadenemas, goals of treat-
ment are to decrease tumor size, improve visual field de-
fects and restore sexual function. Dopomine agonists are
able to reach these goals with reducing tumor size [13,14].
In comparison with bromocriptine, cabergoline has fewer
side effects and more positive effects at normalizing pro-
lactin levels [15]. If visual field defect persists and chias-
mal compression on MRI examination continues despite
optimal medical treatment, surgery will be inevitable. But
little is known about the role of dopamine agonist therapy
in treatment of giant invasive prolactinomas. There were
studies evaluating cabergoline (a dopamine agonist) in
management of giant prolactinoma [14,16,17]. All of these
studies showed that cabergoline is safe and well-tolerated
and also suggested that cabergoline should be the first line
of treatment for giant aggressive macroprolactionomas. InFigure 1 Huge macroprolactinoma with suprasellar invasion
before treatment.one study, cabergoline normalized prolactin levels in ten
out of twelve patient and decreased significantly in the
other two significantly. Visual field defect was present in
nine patients at diagnosis which returned to normal in
three of patients and improved in five after treatment.
Tumor diameter responded to treatment with decrease of
47+/- 21% in size. Testosterone levels returned to normal
in eight out of twelve patients. In this study only two of
patients had secondary hypoadrenalism and hypothyroi-
dism who improved after treatment [14]. Hypothyroidism
and hypoadrenalism improve usually following norma-
lization of prolactin level and tumor size in macro-
prolactinomas [14,15,18] but little is known about their
recovery in giant prolactinoma. Hypogonadism persists
in half of male patients with macroprolactinoma despite
tumor shrinkage and normalization of prolactin levels
[14,16,19,20]. Therefore testosterone replacement is re-
quired to maintain bone strength. Androgen can cause
secondary rises in prolactin levels that postulated to
central aromatization to estrogens [21].
In our case, tumor size markedly reduced and visual
field and ACTH secretion recovered completely afterFigure 2 14 months after treatment; significant tumor
shrinkage.
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nadism and secondary hypothyroidism persisted. Soma-
totroph and gonadotroph cells are the most sensitive
pituitary cells to injury secondary to sellar compression,
but in this case thyrotroph cells also showed impaired
function which did not recover after significant tumor
shrinkage. With our best knowledge, there is not any re-
port about this unusual response of giant prolactin-
producing macroadenoma to cabergoline treatment in
literature.
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